

### REMARKS

Claims 2, 6, 7, and 28 to 30 are in the application, with Claim 2 being independent. Claim 2 has been amended herein, and Claim 30 has been newly added. Reconsideration and further examination are respectfully requested.

Claims 2, 6, 7, 28, and 29 were rejected under 35 U.S.C. § 102(b) over PNAS, Vol. 99, May 28, 2002, pp. 7554 to 7559 (Dudley) and the accompanying "Supplementary Material". These claims were also rejected under 35 U.S.C. § 102(b) over U.S. Publication No. 2002/0051973 (Delenstarr). The rejections are respectfully traversed.

According to a feature of the invention as recited by Claim 2, the DNA micro-array is configured such that the internal standard nucleic acids are added at a known amount to the sample at the time of PCR amplification of said nucleic acid molecules having the target base sequences.

Neither Dudley nor Delenstarr is seen to disclose or suggest at least the above-discussed feature.

The dependent claims are also submitted to be patentable because they set forth additional aspects of the present invention and are dependent from the independent claim discussed above. Therefore, separate and individual consideration of each dependent claim is respectfully requested.

The application is believed to be in condition for allowance, and a Notice of Allowance is respectfully requested.

Applicants' undersigned attorney may be reached in our Costa Mesa, California office by telephone at (714) 540-8700. All correspondence should be directed to our address given below.

Respectfully submitted,

/Damond E. Vadnais/  
Damond E. Vadnais  
Attorney for Applicants  
Registration No. 52,310

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3800  
Facsimile: (212) 218-2200

FCHS\_WS 1708171v1